Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Silence Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Silence Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if Silence Therapeutics is high growth as no earnings estimate data is available.
Silence Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Silence Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Silence Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Silence Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Silence Therapeutics has no long term commitments.
This treemap shows a more detailed breakdown of
Silence Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Silence Therapeutics has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. David Horn Solomon, M.D., has been Chief Executive Officer & Director at Silence Therapeutics plc since July 17, 2018. Dr. Solomon served as Chief Executive Officer of Akari Therapeutics, Plc from August 28, 2017 until May 8, 2018 and was member of the Board of Directors until May 8, 2018. Dr. Solomon was the Managing Partner of Sund Capital, a Nordic healthcare investment fund. He served as Chief Executive Officer and President at Bionor Pharma ASA from January 19, 2015 to April 26, 2016. Dr. Solomon served as the Chief Executive Officer of Zealand Pharma A/S FROM September 2008 to January 15, 2015 and also served as its President. He served as the Chief Scientific Officer of Zealand Pharma A/S October 1, 2013. He has an extensive experience in pharmacology research. He has more than 20 years of experience in medical research, healthcare investing and key biopharmaceutical & medical device operating roles. He served as Executive of Critical Care Diagnostics, Inc. He served as a Member of Executive Management Board at Zealand Pharma A/S. He serves as the Director of Tyler Hill Holdings ApS and Solomon-Solvberg Sons and Daughters. He has a wealth of experience in biotechnology innovation, investor relations, regulatory matters and advancing new medicines to patients and caregivers. He served leadership positions at several biotechnology, pharmaceutical and medical device companies, including Critical Diagnostics. He served as Executive Officer Remedy Pharmaceuticals, Inc. He served as Medical Director of Carrot Capital Healthcare Ventures and Carrot Capital Healthcare Ventures, L.P. He served as the Chief Operating Officer of Vital Sensors, Inc. From 2003 to 2006, he led healthcare investing at Carrot Capital Healthcare Ventures. Dr. Solomon has been Additional Independent Director at TxCell Promesses since April 2015. He served as an Independent Director of Onxeo SA (alternate name BioAlliance Pharma) since June 29, 2011 until April 26, 2017. Dr. Solomon served on various boards in his career. He has taught and lectured at various institutions. He was a Faculty Member of Columbia University's College of Physicians and Surgeons in New York. Dr. Solomon studied medicine and immunology at Cornell Medical College and the Sloan Kettering Cancer Center in New York City where he received his doctorate in 1991.
Insufficient data for David to compare compensation growth.
Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the Silence Therapeutics management team is less than 2 years, this suggests a new team.
CEO & Director
Interim CFO & Company Secretary
Head of Chemistry
Head of Clinical Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Silence Therapeutics board of directors is less than 3 years, this suggests a new board.
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.